• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

系统评价纳入照顾者和家庭成员健康相关生活质量的成本效用分析。

Systematic Review of Cost-Utility Analyses That Have Included Carer and Family Member Health-Related Quality of Life.

机构信息

School of Health and Related Research, University of Sheffield, Sheffield, England, UK.

Institute of Pharmaceutical Medicine (ECPM), University of Basel, Basel, Switzerland.

出版信息

Value Health. 2022 Sep;25(9):1644-1653. doi: 10.1016/j.jval.2022.02.008. Epub 2022 Mar 24.

DOI:10.1016/j.jval.2022.02.008
PMID:35339379
Abstract

OBJECTIVES

Health interventions for patients can also affect the health of their informal carers and family members. These changes in carer or family member health could be reflected in cost-utility analyses (CUAs) through the inclusion of their quality-adjusted life-years (QALYs). We conducted a systematic review to identify and describe all CUAs that have included family member health-related QALYs.

METHODS

A total of 4 bibliographic databases were searched from inception to July 2021. A 2-stage sifting process for inclusion of studies was undertaken. We performed data extraction using a standardized data extraction form and performed a narrative synthesis of the evidence.

RESULTS

A total of 40 CUAs published between 1999 and 2021 were identified. CUAs were conducted in 15 different countries. CUAs examined 13 different conditions including 15 CUAs on vaccination, 5 on Alzheimer's disease, 2 on Parkinson's disease, 3 on dementia, and 2 on terminal illness. The EQ-5D was the most commonly used measure of family member health. Generally, including carer QALYs resulted in lower incremental cost-effectiveness ratios.

CONCLUSIONS

When considering the total number of economic evaluations published, few have included family member QALYs and the methods for doing so are often inconsistent and data sources often limited. Estimation of family member QALYs in patient CUAs was regularly uncertain and often substantial in magnitude. The findings highlight the variation among methods and call for greater consistency in methods for incorporating family member QALYs in patient CUAs.

摘要

目的

患者的健康干预措施也会影响其非正式照顾者和家庭成员的健康。这些照顾者或家庭成员健康状况的变化可以通过纳入他们的质量调整生命年(QALY)来反映在成本效用分析(CUA)中。我们进行了一项系统评价,以确定和描述所有纳入了家庭成员健康相关 QALY 的 CUA。

方法

从开始到 2021 年 7 月,共搜索了 4 个文献数据库。进行了 2 阶段的研究筛选过程。我们使用标准化的数据提取表格提取数据,并对证据进行叙述性综合。

结果

共确定了 1999 年至 2021 年间发表的 40 项 CUA。CUA 是在 15 个不同的国家进行的。CUA 研究了 13 种不同的疾病,包括 15 项疫苗接种 CUA、5 项阿尔茨海默病 CUA、2 项帕金森病 CUA、3 项痴呆症 CUA 和 2 项终末期疾病 CUA。EQ-5D 是最常用于衡量家庭成员健康的测量工具。通常,包括照顾者的 QALY 会导致更低的增量成本效益比。

结论

考虑到已发表的经济评估总数,很少有包括家庭成员 QALY 的评估,而且这些评估的方法往往不一致,数据来源也往往有限。在患者 CUA 中估算家庭成员的 QALY 通常是不确定的,而且往往具有很大的不确定性。这些发现突出了方法之间的差异,并呼吁在患者 CUA 中纳入家庭成员 QALY 的方法更加一致。

相似文献

1
Systematic Review of Cost-Utility Analyses That Have Included Carer and Family Member Health-Related Quality of Life.系统评价纳入照顾者和家庭成员健康相关生活质量的成本效用分析。
Value Health. 2022 Sep;25(9):1644-1653. doi: 10.1016/j.jval.2022.02.008. Epub 2022 Mar 24.
2
The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review.戈谢病酶替代疗法的临床疗效和成本效益:一项系统评价。
Health Technol Assess. 2006 Jul;10(24):iii-iv, ix-136. doi: 10.3310/hta10240.
3
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.拓扑替康治疗卵巢癌的临床有效性和成本效益的快速系统评价。
Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280.
4
Interventions for interpersonal communication about end of life care between health practitioners and affected people.干预健康从业者与受影响者之间关于临终关怀的人际沟通。
Cochrane Database Syst Rev. 2022 Jul 8;7(7):CD013116. doi: 10.1002/14651858.CD013116.pub2.
5
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.利用预后信息为乳腺癌患者选择辅助性全身治疗的成本效益
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340.
6
Survivor, family and professional experiences of psychosocial interventions for sexual abuse and violence: a qualitative evidence synthesis.性虐待和暴力的心理社会干预的幸存者、家庭和专业人员的经验:定性证据综合。
Cochrane Database Syst Rev. 2022 Oct 4;10(10):CD013648. doi: 10.1002/14651858.CD013648.pub2.
7
Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.拓扑替康、聚乙二醇化脂质体盐酸多柔比星和紫杉醇用于晚期卵巢癌二线或后续治疗:一项系统评价和经济学评估
Health Technol Assess. 2006 Mar;10(9):1-132. iii-iv. doi: 10.3310/hta10090.
8
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
9
A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment.促红细胞生成素α、促红细胞生成素β和达比加群酯治疗癌症相关性贫血(尤其是癌症治疗所致贫血)的系统评价与经济学评估
Health Technol Assess. 2007 Apr;11(13):1-202, iii-iv. doi: 10.3310/hta11130.
10
Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.阿德福韦酯与聚乙二醇化干扰素α-2a治疗慢性乙型肝炎:系统评价与经济学评估
Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. doi: 10.3310/hta10280.

引用本文的文献

1
Stakeholder survey about broad elements of value in health technology assessment in Australia: industry and academia more similar than different.关于澳大利亚卫生技术评估中广泛价值要素的利益相关者调查:行业与学术界的相似之处多于不同之处。
Int J Technol Assess Health Care. 2025 Jul 8;41(1):e61. doi: 10.1017/S0266462325100226.
2
The Burden of Adult X-Linked Hypophosphatemia on Carers and Family Members: A Mixed-Methods Study.成人X连锁低磷血症对护理人员和家庭成员的负担:一项混合方法研究。
J Health Econ Outcomes Res. 2025 Apr 24;12(1):162-170. doi: 10.36469/001c.133860. eCollection 2025.
3
How Does Bereavement Affect the Health-Related Quality of Life of Household Members Who Do and Do Not Provide Unpaid Care? Difference-in-Differences Analyses Using the UK Household Longitudinal Survey.
丧亲之痛如何影响提供和不提供无偿护理的家庭成员的健康相关生活质量?利用英国家庭纵向调查进行的双重差分分析。
Pharmacoeconomics. 2025 Apr;43(4):389-402. doi: 10.1007/s40273-024-01452-1. Epub 2024 Dec 5.
4
Development of stakeholder-informed recommendations for inclusion of family spillover effects in health technology assessment.制定利益相关者知情的建议,以纳入健康技术评估中的家庭溢出效应。
J Manag Care Spec Pharm. 2024 Sep;30(9):1013-1024. doi: 10.18553/jmcp.2024.30.9.1013.
5
Emollient application from birth to prevent eczema in high-risk children: the BEEP RCT.从出生开始使用保湿剂预防高危儿童特应性皮炎:BEEP RCT。
Health Technol Assess. 2024 Jul;28(29):1-116. doi: 10.3310/RHDN9613.
6
Economic Evaluations of Treatments for Duchenne Muscular Dystrophy: The Caregiver QALY Trap.杜氏肌营养不良症治疗的经济评估:照顾者质量调整生命年陷阱
Pharmacoeconomics. 2024 May;42(5):475-478. doi: 10.1007/s40273-024-01367-x. Epub 2024 Mar 5.
7
On spillovers in economic evaluations: definition, mapping review and research agenda.关于经济评估中的溢出效应:定义、映射综述和研究议程。
Eur J Health Econ. 2024 Sep;25(7):1239-1260. doi: 10.1007/s10198-023-01658-8. Epub 2024 Jan 23.
8
Recommendations for Emerging Good Practice and Future Research in Relation to Family and Caregiver Health Spillovers in Health Economic Evaluations: A Report of the SHEER Task Force.关于健康经济评估中家庭和照护者健康溢出效应的新兴良好实践和未来研究建议:SHEER 工作组的报告。
Pharmacoeconomics. 2024 Mar;42(3):343-362. doi: 10.1007/s40273-023-01321-3. Epub 2023 Dec 2.
9
Modelling Informal Carers' Health-Related Quality of Life: Challenges for Economic Evaluation.建模非正规照护者的健康相关生活质量:经济评估面临的挑战。
Appl Health Econ Health Policy. 2024 Jan;22(1):9-16. doi: 10.1007/s40258-023-00834-4. Epub 2023 Nov 10.
10
A Systematic Review of Methods Used by Pediatric Cost-Utility Analyses to Include Family Spillover Effects.儿童成本效用分析纳入家庭溢出效应的方法系统评价
Pharmacoeconomics. 2024 Feb;42(2):199-217. doi: 10.1007/s40273-023-01331-1. Epub 2023 Nov 9.